I'm an Ivy League student at Columbia with schizophrenia, which causes hallucinations. I always see eels and lemons, so it's ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

London: Neurocrine Biosciences said it will halt the development of its experimental drug, aimed at improving cognitive ...

Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological ...

RVPH RECOVER Vocal Biomarker Data On September 4, 2024, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a k ey ...

In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.

Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

Additionally, improvement in positive symptoms contributed to some ... of treatment with olanzapine favorably affects cognitive functioning in schizophrenia, with strong beneficial effects ...